REPLIMUNE GROUP, INC. Shareholders' Equity
REPLIMUNE GROUP, INC. (REPL) had Shareholders' Equity of $105.64 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity Attributable to Parent $105.64M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $166.16M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $210.54M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $263.34M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $105.64M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $166.16M 10-Q · filed 2026-08-14 |
| 2025-12-31 | $210.54M 10-Q · filed 2026-02-03 |
| 2025-09-30 | $263.34M 10-Q · filed 2026-02-03 |
| 2025-06-30 | $336.71M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $415.84M 10-Q · filed 2026-08-14 |
| 2024-12-31 | $482.37M 10-Q · filed 2026-02-03 |
| 2024-09-30 | $381.46M 10-Q · filed 2026-02-03 |
| 2024-06-30 | $426.45M 10-Q · filed 2026-02-03 |
| 2024-03-31 | $374.51M 10-K · filed 2026-06-29 |
| 2023-12-31 | $421.54M 10-Q · filed 2025-02-12 |
| 2023-09-30 | $465.17M 10-Q · filed 2025-02-12 |
| 2023-06-30 | $514.03M 10-Q · filed 2025-02-12 |
| 2023-03-31 | $555.29M 10-K · filed 2025-05-22 |
| 2022-12-31 | $595.35M 10-Q · filed 2024-02-08 |
| 2022-09-30 | $384.07M 10-Q · filed 2024-02-08 |
| 2022-06-30 | $410.26M 10-Q · filed 2024-02-08 |
| 2022-03-31 | $411.23M 10-K · filed 2024-05-16 |
| 2021-12-31 | $437.51M 10-Q · filed 2023-02-09 |
| 2021-09-30 | $457.41M 10-Q · filed 2023-02-09 |
| 2021-06-30 | $479.02M 10-Q · filed 2023-02-09 |
| 2021-03-31 | $498.73M 10-K · filed 2023-05-18 |
| 2020-12-31 | $516.20M 10-Q · filed 2022-02-03 |
| 2020-09-30 | $261.39M 10-Q · filed 2022-02-03 |
| 2020-06-30 | $277.81M 10-Q · filed 2022-02-03 |
| 2020-03-31 | $183.72M 10-K · filed 2022-05-19 |
| 2019-12-31 | $197.56M 10-Q · filed 2021-02-04 |
| 2019-09-30 | $120.64M 10-Q · filed 2021-02-04 |
| 2019-06-30 | $130.15M 10-Q · filed 2021-02-04 |
| 2019-03-31 | $137.86M 10-K · filed 2021-05-20 |
| 2018-12-31 | $143.24M 10-Q · filed 2020-02-13 |
| 2018-09-30 | $150.04M 10-Q · filed 2020-02-13 |
| 2018-06-30 | -$38.70M 10-Q · filed 2020-02-13 |
| 2018-03-31 | -$28.07M 10-K · filed 2020-06-03 |
| 2017-03-31 | -$11.52M 10-K · filed 2020-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |